Investor Presentaiton
Serplulimab: Targeting Differentiated Indications
D
Gastric Cancer
1
(GC)
Neoadjuvant treatment in combination with
Chemotherapy / Adjuvant with Serplulimab only
Phase III clinical data readout: H1 2025
2
3
According to the baseline data analysis of 649 subjects in the Checkmate, 60% advanced GC
patients had CPS ≥ 5. The trial design had focused on PD-L1-positive patients (CPS ≥ 5) from
the very beginning. Serplulimab aims to be the world leading and China's only perioperative
I/O treatment for GC
Around 2/3 of 400,000 new GC cases in China every year 1,2 were suitable for perioperative
treatments. With the increasing penetration of gastroscopy examinations, more GC cases will be
detected
Currently, the median EFS of perioperative SoC for GC is ~3 years. It is estimated that most
patients can be treated with Serplulimab for up to 20 treatment cycles (the maximum duration set
by the trial protocol) if the trial succeeds
26
Limited Stage Small
1
00
Cell Lung Cancer
(LS-SCLC)
Serplulimab combined with Concurrent
Chemoradiotherapy (CCRT)
Phase III clinical data readout: H2 2026
2
3
Globally, the incidence for lung cancer ranks #2 and the mortality ranks #1. In China, both
incidence and mortality of lung cancers ranks #1. Among 820,000 new cases of lung cancers
in China every year, 15% is SCLC. Among SCLC patents, about 30%-40% are LS-SCLC³
Phase III MRCT had 238 patients enrolled as of Dec. 2023, from mainland China, Hong Kong
SAR, Australia, the US, etc.; by Oct. 2023, the first patient has been dosed in the EU
Concurrent chemoradiotherapy (CCRT) is the SoC for LS-SCLC and globally no PD-1/PD-L1
was approved yet for this indication. Serplulimab can potentially become the world's first
PD-1 mAb for LS-SCLC treatment if the trial succeeds
1. Zheng RS et al. 2016 China cancer prevalence analysis. Chinese Journal of Oncololgy, 2023, 45(3): 212-220. DOI: 10.3760/cma.j.cn112152-20220922-00647
2. Strong, Vivian E et al. “Differences in gastric cancer survival between the U.S. and China." Journal of surgical oncology vol. 112,1 (2015): 31-7. doi:10.1002/jso.23940
3. Ha IB, Jeong BK, Jeong H, et al. Effect of early chemoradiotherapy in patients with limited stage small cell lung cancer. Radiat Oncol J. 2013 Dec;31(4):185-90
© 2024 Henlius.
2 HenliusView entire presentation